# US 2010/0166742 A1 · Method for promoting immunotherapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166742 A1
- Document ID: US20100166742A1
- Status: Published application
- Kind: A1
- Application number: 12/440,319
- Filed: 2007-09-07
- Published: 2010-07-01
- Earliest claimed: 2006-09-07
- Assignees: Fresenius Medical Care Deutschland GmbH
- Inventors: Martin Hepper; Hans Peter Leinenbach; Frank Nocken
- Web page: https://patentgrep.com/patent/US20100166742A1

## CPC

- C07K 16/4283: {against an allotypic or isotypic determinant on Ig}
- C07K 16/32: against translation products of oncogenes
- A61M 1/3679: {by absorption (A61M1/3675 takes precedence)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

The present invention relates to an ex vivo method for increasing the effectiveness of antibodies and Fcγ receptor-binding active ingredients, comprising the steps of: a) preparing a blood sample of a patient; b) subjecting the blood sample to an immunoapheresis; c) administering a therapeutically effective antibody or an Fcγ receptor-binding active ingredient to the patient.

## Claims

### Claim 1

Ex-vivo method for increasing the effectiveness of antibodies and Fcγ receptor-binding active ingredients, comprising the steps of:
a) preparing a blood sample of a patient;
b) subjecting the blood sample to an immunoapheresis;
c) administering a therapeutically effective antibody or an Fcγ receptor-binding active ingredient to a patient.

### Claim 2 (depends on 1)

Method according to claim 1, wherein the blood sample subjected to an immunoapheresis is administered to the patient before or after step c).

### Claim 3 (depends on 1)

Method according to claim 1, wherein in step b) antibodies are removed from the blood sample.

### Claim 4 (depends on 3)

Method according to claim 3, wherein the removed antibodies are re-administered to the patient following step c).

### Claim 5 (depends on 3)

Method according to claim 3, wherein the removed antibodies are human anti-species antibodies.

### Claim 6 (depends on 3)

Method according to claim 3, wherein the removed antibodies are autologous antibodies with Fcγ receptor-binding epitopes.

### Claim 7 (depends on 1)

Method according to claim 1, wherein step b) is carried out several times.

### Claim 8 (depends on 1)

Method according to claim 1, wherein the blood sample is human blood or blood plasma.

### Claim 9 (depends on 1)

Method according to claim 1, further comprising the step of the administration of a medicinal product.

### Claim 10 (depends on 9)

Method according to claim 9, wherein the medicinal product is a chemotherapeutic or a cytostatic.

### Claim 11 (depends on 9)

Method according to claim 9, wherein the medicinal product is selected from a group comprising paclitaxel, lenalidomide, pomalidomide, epirubicin, 5FU and its derivatives, and kinase inhibitors such as sunitinib, lapatinib, canertinib, or combinations of various medicinal products selected from the group comprising CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone (steroid), lenalidomide/dexamethasone, pomalidomide/dexamethasone and paclitaxel/carboplatin.

### Claim 12 (depends on 1)

Method according to claim 1, wherein the therapeutically effective antibody is a bispecific antibody.

### Claim 13 (depends on 1)

Method according to claim 1, wherein the therapeutically effective antibody is a bispecific trifunctional antibody.

### Claim 14 (depends on 13)

Method according to claim 13, wherein the bispecific trifunctional antibody is a mouse/rat/IgG2a/IgG2b chimera.

### Claim 15

Use of a combination of one or more medicinal products together with FcR-binding immunoglobulins, fragments of immunoglobulins or fusion proteins, to prepare a medicament for the treatment of cancer and/or autoimmune diseases and/or of patients who have had a transplant and/or for vaccination against viruses, wherein the treatment comprises the steps of:
a) preparing a blood sample of a patient;
b) subjecting the blood sample to an immunoapheresis;
c) administering a therapeutically effective antibody to the patient.

### Claim 16 (depends on 15)

Use according to claim 15, wherein the blood sample subjected to an immunoapheresis is administered to the patient before or after step c).

### Claim 17 (depends on 15)

Use according to claim 15, wherein in step b) antibodies are removed from the blood sample.

### Claim 18 (depends on 15)

Use according to claim 15, wherein the removed antibodies are re-administered to the patient following step c).

### Claim 19 (depends on 17)

Use according to claim 17, wherein the removed antibodies are human anti-species antibodies.

### Claim 20 (depends on 17)

Use according to claim 17, wherein the removed antibodies are autologous antibodies with Fcγ receptor-binding epitopes.

### Claim 21 (depends on 15)

Use according to claim 15, wherein step b) is carried out several times.

### Claim 22 (depends on 15)

Use according to claim 15, wherein the blood sample is human blood or blood plasma.

### Claim 23 (depends on 15)

Use according to one of claim 15, further comprising the administration of a medicinal.

### Claim 24 (depends on 15)

Use according to one of claim 15, wherein the medicinal product is a chemotherapeutic or a cytostatic.

### Claim 25 (depends on 23)

Use according to claim 23, wherein the medicinal product is selected from a group comprising paclitaxel, lenalidomide, pomalidomide, epirubicin, 5FU and its derivatives, and kinase inhibitors such as sunitinib, lapatinib, canertinib, or combinations of various medicinal products, selected from the group comprising CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone (steroid), lenalidomide/dexamethasone, pomalidomide/dexamethasone and paclitaxel/carboplatin.

### Claim 26 (depends on 15)

Use according to claim 15, wherein the therapeutically effective antibody is a bispecific antibody.

### Claim 27 (depends on 15)

Use according to claim 15, wherein the therapeutically effective antibody is a bispecific, trifunctional antibody.

### Claim 28 (depends on 15)

Use according to claim 15, wherein the therapeutically effective antibody is a humanized or IgG-like antibody.

### Claim 29 (depends on 27)

Use according to claim 27, wherein the bispecific, trifunctional antibody is a mouse/rat/IgG2a/IgG2b chimera.

### Claim 30

Use of specific ligands for autologous antibodies with Fcγ receptor-binding regions to prepare a column which has the specific ligand coupled to it, for the treatment of a patient with Fcγ receptor-binding active ingredients, wherein the treatment comprises the steps of:
a) preparing a blood sample of a patient;
b) subjecting the blood sample to an immunoapheresis;
c) administering an Fcγ receptor-binding active ingredient to the patient.

### Claim 31

Use of specific ligands for autologous antibodies to prepare a column which has the ligand coupled to it, for the treatment of a patient with therapeutic antibodies, wherein the treatment comprises the steps of:
a) preparing a blood sample of a patient;
b) subjecting the blood sample to an immunoapheresis;
c) administering a therapeutically effective antibody to the patient.

### Claim 32

Use of specific ligands for cancer-associated antigens soluble in blood samples to prepare a column which has the ligand coupled to it, for the treatment of a patient with therapeutic antibodies, wherein the treatment comprises the steps of:
a) preparing a blood sample of a patient;
b) subjecting the blood sample to an immunoapheresis;
c) administering a therapeutically effective antibody to the patient.

### Claim 33 (depends on 30)

Use according to claim 30, wherein the matrix of the column consists of sepharose or acrylic compounds.

### Claim 34 (depends on 33)

Use according to claim 33, wherein the matrix is activated with CN—Br before the application of the ligand.

### Claim 35 (depends on 30)

Use according to claim 30, wherein protein A, protein G, peptides and/or anti-antibodies are used as ligands.

### Claim 36

Use of Fcγ receptor-binding active ingredients to prepare a medicament for the treatment of cancer and/or autoimmune diseases and/or of patients who have had a transplant and/or for vaccination against viruses, wherein the treatment comprises the steps of:
a) preparing a blood sample of a patient;
b) subjecting the blood sample to an immunoapheresis;
c) administering the medicament to the patient.

### Claim 37 (depends on 30)

Use according to claim 30, wherein the Fcγ receptor-binding active ingredient is a therapeutic antibody.

### Claim 38 (depends on 30)

Use according to claim 30, further comprising the administration of a medicinal product.

### Claim 39 (depends on 38)

Use according to claim 38, wherein the medicinal product is a chemotherapeutic or cytostatic.

### Claim 40 (depends on 38)

Use according to claim 38, wherein the medicinal product is selected from a group comprising paclitaxel, lenalidomide, pomalidomide, epirubicin, 5FU and its derivatives, and kinase inhibitors such as sunitinib, lapatinib, canertinib, or combinations of various medicinal products, selected from the group comprising CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone (steroid), lenalidomide/dexamethasone, pomalidomide/dexamethasone and paclitaxel/carboplatin.

### Claim 41 (depends on 30)

Use according to claim 30, wherein the therapeutically effective antibody is a bispecific antibody.

### Claim 42 (depends on 30)

Use according to claim 30, wherein the therapeutically effective antibody is a bispecific trifunctional antibody.

### Claim 43 (depends on 42)

Method according to claim 42, wherein the bispecific trifunctional antibody is a mouse/rat/IgG2a/IgG2b chimera.
